These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15333483)

  • 1. Temporary preservation of beta-cell function by diazoxide treatment in childhood type 1 diabetes.
    Ortqvist E; Björk E; Wallensteen M; Ludvigsson J; Aman J; Johansson C; Forsander G; Lindgren F; Berglund L; Bengtsson M; Berne C; Persson B; Karlsson FA
    Diabetes Care; 2004 Sep; 27(9):2191-7. PubMed ID: 15333483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes.
    Björk E; Berne C; Kämpe O; Wibell L; Oskarsson P; Karlsson FA
    Diabetes; 1996 Oct; 45(10):1427-30. PubMed ID: 8826981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of beta-cell rest in type 1 diabetes. Studies on the effects of octreotide and diazoxide.
    Björk E; Berne C; Karlsson FA
    Diabetes Care; 1998 Mar; 21(3):427-30. PubMed ID: 9540027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved beta cell function after short-term treatment with diazoxide in obese subjects with type 2 diabetes.
    Guldstrand M; Grill V; Björklund A; Lins PE; Adamson U
    Diabetes Metab; 2002 Dec; 28(6 Pt 1):448-56. PubMed ID: 12522324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional rest through intensive treatment with insulin and potassium channel openers preserves residual beta-cell function and mass in acutely diabetic BB rats.
    Rasmussen SB; Sørensen TS; Hansen JB; Mandrup-Poulsen T; Hornum L; Markholst H
    Horm Metab Res; 2000 Jul; 32(7):294-300. PubMed ID: 10965937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partial inhibition of insulin secretion results in glucose intolerance but not hyperglucagonemia.
    Ramanathan RP; Arbeláez AM; Cryer PE
    Diabetes; 2011 Apr; 60(4):1324-8. PubMed ID: 21378174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial.
    Raz I; Elias D; Avron A; Tamir M; Metzger M; Cohen IR
    Lancet; 2001 Nov; 358(9295):1749-53. PubMed ID: 11734230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twelve weeks' treatment with diazoxide without insulin supplementation in Type 2 diabetes is feasible but does not improve insulin secretion.
    Radtke M; Kollind M; Qvigstad E; Grill V
    Diabet Med; 2007 Feb; 24(2):172-7. PubMed ID: 17257280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GAD treatment and insulin secretion in recent-onset type 1 diabetes.
    Ludvigsson J; Faresjö M; Hjorth M; Axelsson S; Chéramy M; Pihl M; Vaarala O; Forsander G; Ivarsson S; Johansson C; Lindh A; Nilsson NO; Aman J; Ortqvist E; Zerhouni P; Casas R
    N Engl J Med; 2008 Oct; 359(18):1909-20. PubMed ID: 18843118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effects of K-ATP channel openers in diabetes: an update on mechanisms and clinical experiences.
    Grill V; Radtke M; Qvigstad E; Kollind M; Björklund A
    Diabetes Obes Metab; 2009 Nov; 11 Suppl 4():143-8. PubMed ID: 19817796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nine weeks of bedtime diazoxide is well tolerated and improves beta-cell function in subjects with Type 2 diabetes.
    Qvigstad E; Kollind M; Grill V
    Diabet Med; 2004 Jan; 21(1):73-6. PubMed ID: 14706058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No effect of inhibition of insulin secretion by diazoxide on weight loss in hyperinsulinaemic obese subjects during an 8-week weight-loss diet.
    Due A; Flint A; Eriksen G; Møller B; Raben A; Hansen JB; Astrup A
    Diabetes Obes Metab; 2007 Jul; 9(4):566-74. PubMed ID: 17587399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is type 2 diabetes a different disease in obese and nonobese patients?
    Prando R; Cheli V; Melga P; Giusti R; Ciuchi E; Odetti P
    Diabetes Care; 1998 Oct; 21(10):1680-5. PubMed ID: 9773730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
    Keymeulen B; Vandemeulebroucke E; Ziegler AG; Mathieu C; Kaufman L; Hale G; Gorus F; Goldman M; Walter M; Candon S; Schandene L; Crenier L; De Block C; Seigneurin JM; De Pauw P; Pierard D; Weets I; Rebello P; Bird P; Berrie E; Frewin M; Waldmann H; Bach JF; Pipeleers D; Chatenoud L
    N Engl J Med; 2005 Jun; 352(25):2598-608. PubMed ID: 15972866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolbutamide and diazoxide influence insulin secretion by changing the concentration but not the action of cytoplasmic Ca2+ in beta-cells.
    Mariot P; Gilon P; Nenquin M; Henquin JC
    Diabetes; 1998 Mar; 47(3):365-73. PubMed ID: 9519741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of D-phenylalanine-derivative hypoglycemic agent A-4166 on pancreatic alpha- and beta-cells: comparative study with glibenclamide.
    Hirose H; Maruyama H; Seto Y; Ito K; Fujita T; Dan K; Kanda N; Saruta T; Kato R
    Pharmacology; 1995 Mar; 50(3):175-81. PubMed ID: 7746834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved beta-cell survival and reduced insulitis in a type 1 diabetic rat model after treatment with a beta-cell-selective K(ATP) channel opener.
    Skak K; Gotfredsen CF; Lundsgaard D; Hansen JB; Sturis J; Markholst H
    Diabetes; 2004 Apr; 53(4):1089-95. PubMed ID: 15047626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive deterioration of beta-cell function in nonobese type 2 diabetic subjects. Postprandial plasma C-peptide level is an indication of insulin dependency.
    Prando R; Odetti P; Melga P; Giusti R; Ciuchi E; Cheli V
    Diabetes Metab; 1996 Jun; 22(3):185-91. PubMed ID: 8697306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.